Eric Stephen Winer, MD

Quick facts

Phase 2 pipeline

• BXCL701 · Immunology
  BXCL701 is a selective inhibitor of sphingosine-1-phosphate receptor 1 (S1P1) that modulates immune cell trafficking and reduces pathological inflammation.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Eric Stephen Winer, MD portfolio CI brief
• Eric Stephen Winer, MD pipeline updates RSS